US20050202089A1 - Sustained-release pharmaceutical formulations containing mizolastine - Google Patents

Sustained-release pharmaceutical formulations containing mizolastine Download PDF

Info

Publication number
US20050202089A1
US20050202089A1 US11/027,680 US2768005A US2005202089A1 US 20050202089 A1 US20050202089 A1 US 20050202089A1 US 2768005 A US2768005 A US 2768005A US 2005202089 A1 US2005202089 A1 US 2005202089A1
Authority
US
United States
Prior art keywords
mizolastine
sustained
release
tablet
organic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/027,680
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to US11/027,680 priority Critical patent/US20050202089A1/en
Publication of US20050202089A1 publication Critical patent/US20050202089A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel sustained-release pharmaceutical formulations containing 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperid-4-yl]methylamino]-pyrimidin-4-ol or 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperid-4-yl]methylamino]-pyrimidine-4(1H)-one, or mizolastine, as active principle.
  • Mizolastine is described in European patent EP 0,217,700.
  • Mizolastine binds to the H 1 histamine receptor and inhibits the degranulation of mastocytes in vitro and in vivo. It can thus be used for the treatment of respiratory, cutaneous or ocular allergies and various allergic manifestations.
  • the Applicant Company has based its research of such formulations on the study of the kinetics of dissolution of mizolastine.
  • mizolastine is a weak base (pK 5.6) which is sparingly soluble in water (13 mg/l at neutral pH) but much more soluble at acidic pH (11 g/l at pH 3); the first gelatin capsules released 100% of mizolastine over 30 minutes in a dissolution medium at pH 2 whereas only 40% were dissolved at pH 6.8.
  • the release of mizolastine from the sustained-release pharmaceutical form according to the invention did not need to be influenced by the differences in pH in the gastrointestinal tract.
  • the aim of the present invention is to propose formulations containing mizolastine whose dissolution profile is as follows:
  • the Applicant Company has shown that tablets containing a core formed of a sustained-release tablet containing mizolastine combined with a fatty matrix and with an organic acid, the said tablet being coated to prevent degradation of the product by light, are entirely suitable.
  • the tablets according to the invention contain from 1 mg to 25 mg of mizolastine. These doses correspond to concentrations of from 0.5% to 12% by weight of mizolastine.
  • the fatty matrix is made with hydrogenated castor oil or with hydrogenated lecithins or long-chain fatty acids, for example C 12 -C 28 long chain fatty acids such as behenic acid, or triglycerides esterified with medium-chain fatty acids, for example C 8 -C 18 fatty acids.
  • the organic acid preferably having a pK of 2 or more is chosen from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acids in the form of racemates or isomers.
  • the acid particularly preferred is L-tartaric acid.
  • the weight ratio between the mizolastine and the organic acid should be between 0.3 and 1. With L-tartaric acid, this ratio is preferably equal to 0.5.
  • the tablets are prepared by granulation using the active principle, the agent constituting the fatty matrix, the organic acid and other excipients such as, for example, lactose, mannitol and sugars or similar sugar-alcohols, microcrystalline cellulose, starch, calcium phosphates and sulphates, polyvidone, and substituted celluloses such as hydroxypropyl-cellulose, hydroxypropylmethylcellulose or methylcellulose.
  • the agent constituting the fatty matrix
  • the organic acid and other excipients such as, for example, lactose, mannitol and sugars or similar sugar-alcohols, microcrystalline cellulose, starch, calcium phosphates and sulphates, polyvidone, and substituted celluloses such as hydroxypropyl-cellulose, hydroxypropylmethylcellulose or methylcellulose.
  • the granulation may be carried out in a wet phase, for example in the presence of water or alcohol, or may be performed by fusion or by compacting.
  • the granulation step may optionally be left out and the tablets prepared by direct tableting of the mixture of mizolastine and the excipients.
  • Anhydrous colloidal silica and magnesium stearate are added to the granules obtained and the mixture is tableted.
  • the tablets are then covered with a coating film by spraying them with a coating solution in a machine with a fluidized-air bed or in a coating turbine.
  • This profile gives about 50% of product dissolved in 1 hour, 100% of product dissolved in 3 to 5 hours, and it is independent of the pH.
  • the plasma kinetics of a pharmaceutical form according to the invention containing 10 mg of mizolastine were studied in a healthy volunteer after a single oral administration, compared with a standard immediate-release gelatin capsule containing 10 mg of mizolastine.
  • Table 1 presents the kinetic parameters and FIG. 3 the curves of the plasma kinetics, obtained respectively with each formulation; the plasma kinetics obtained with the pharmaceutical form according to the invention makes it possible to prevent any peak in the plasma without losing bioavailability.
  • the plasma kinetics of a pharmaceutical form according to the invention were also studied in comparison with the same formulation without L-tartaric acid.
  • Table 2 shows that the bioavailability of the formulation containing no L-tartaric acid represents only 43% of that observed with the formulation according to the invention containing L-tartaric acid.
  • the values of Cmax and the AUC values (0- ⁇ ) are respectively 1.5 and 2 times as high for the formulation containing L-tartaric acid as for that not containing any.

Abstract

A sustained-release pharmaceutical formulation containing mizolastine, a core formed of a sustained-release table containing mizolastine combined with a fatty matrix and an organic acid, the tablet being coated.

Description

  • The present invention relates to novel sustained-release pharmaceutical formulations containing 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperid-4-yl]methylamino]-pyrimidin-4-ol or 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperid-4-yl]methylamino]-pyrimidine-4(1H)-one, or mizolastine, as active principle.
  • Mizolastine is described in European patent EP 0,217,700.
  • Mizolastine binds to the H1 histamine receptor and inhibits the degranulation of mastocytes in vitro and in vivo. It can thus be used for the treatment of respiratory, cutaneous or ocular allergies and various allergic manifestations.
  • During the oral administration of immediate-release formulations containing mizolastine, undesirable sedative effects have been observed which are associated with the existence of a high peak in the plasma.
  • Consequently, it was necessary to find formulations for an oral administration which have a profile of release of the active principle such that it is possible to obtain a lower peak in the plasma without decreasing the bioavailability.
  • The Applicant Company has based its research of such formulations on the study of the kinetics of dissolution of mizolastine. The reason for this is that mizolastine is a weak base (pK 5.6) which is sparingly soluble in water (13 mg/l at neutral pH) but much more soluble at acidic pH (11 g/l at pH 3); the first gelatin capsules released 100% of mizolastine over 30 minutes in a dissolution medium at pH 2 whereas only 40% were dissolved at pH 6.8.
  • Moreover, the release of mizolastine from the sustained-release pharmaceutical form according to the invention did not need to be influenced by the differences in pH in the gastrointestinal tract.
  • The aim of the present invention is to propose formulations containing mizolastine whose dissolution profile is as follows:
      • about 30 to 70% of mizolastine dissolved in 1 hour,
      • 100% of mizolastine dissolved in 3 to 5 hours, and
      • pH-independent profile.
  • The Applicant Company has shown that tablets containing a core formed of a sustained-release tablet containing mizolastine combined with a fatty matrix and with an organic acid, the said tablet being coated to prevent degradation of the product by light, are entirely suitable.
  • The tablets according to the invention contain from 1 mg to 25 mg of mizolastine. These doses correspond to concentrations of from 0.5% to 12% by weight of mizolastine.
  • The fatty matrix is made with hydrogenated castor oil or with hydrogenated lecithins or long-chain fatty acids, for example C12-C28 long chain fatty acids such as behenic acid, or triglycerides esterified with medium-chain fatty acids, for example C8-C18 fatty acids.
  • The organic acid preferably having a pK of 2 or more is chosen from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acids in the form of racemates or isomers. According to the invention, the acid particularly preferred is L-tartaric acid.
  • The weight ratio between the mizolastine and the organic acid should be between 0.3 and 1. With L-tartaric acid, this ratio is preferably equal to 0.5.
  • The tablets are prepared by granulation using the active principle, the agent constituting the fatty matrix, the organic acid and other excipients such as, for example, lactose, mannitol and sugars or similar sugar-alcohols, microcrystalline cellulose, starch, calcium phosphates and sulphates, polyvidone, and substituted celluloses such as hydroxypropyl-cellulose, hydroxypropylmethylcellulose or methylcellulose.
  • The granulation may be carried out in a wet phase, for example in the presence of water or alcohol, or may be performed by fusion or by compacting. The granulation step may optionally be left out and the tablets prepared by direct tableting of the mixture of mizolastine and the excipients.
  • Anhydrous colloidal silica and magnesium stearate are added to the granules obtained and the mixture is tableted. The tablets are then covered with a coating film by spraying them with a coating solution in a machine with a fluidized-air bed or in a coating turbine.
  • The example which follows illustrates the invention without limiting it:
    % (weight)
    Tablet
    mizolastine 4.8
    hydrogenated castor oil 12.0
    lactose 60.0
    microcrystalline cellulose 9.6
    L-tartaric acid 9.6
    polyvidone 2.9
    anhydrous colloidal silica 0.2
    magnesium stearate 0.9
    purified water Q.S.
    Total 100.0
    Coating
    methylhydroxypropylcellulose 74.0
    titanium dioxide (E171) 18.5
    propylene glycol 7.5
    purified water Q.S.
    Total 100.0
  • The dissolution profile obtained with a formulation according to the invention is given in FIG. 1.
  • This profile gives about 50% of product dissolved in 1 hour, 100% of product dissolved in 3 to 5 hours, and it is independent of the pH.
  • The dissolution profile obtained with a formulation identical to that of the invention but containing no L-tartaric acid is given in FIG. 2.
  • The plasma kinetics of a pharmaceutical form according to the invention containing 10 mg of mizolastine were studied in a healthy volunteer after a single oral administration, compared with a standard immediate-release gelatin capsule containing 10 mg of mizolastine.
  • Table 1 presents the kinetic parameters and FIG. 3 the curves of the plasma kinetics, obtained respectively with each formulation; the plasma kinetics obtained with the pharmaceutical form according to the invention makes it possible to prevent any peak in the plasma without losing bioavailability.
  • The plasma kinetics of a pharmaceutical form according to the invention were also studied in comparison with the same formulation without L-tartaric acid.
  • The study was performed on twelve healthy volunteers after a single oral administration of a tablet according to the invention containing 10 mg of mizolastine or the same tablet without L-tartaric acid.
  • Table 2 shows that the bioavailability of the formulation containing no L-tartaric acid represents only 43% of that observed with the formulation according to the invention containing L-tartaric acid. The values of Cmax and the AUC values (0-∞) are respectively 1.5 and 2 times as high for the formulation containing L-tartaric acid as for that not containing any.
  • In addition, for the formulation with L-tartaric acid, the min.-max. variation indices are much lower, which suggests great uniformity in the release.
  • The results altogether show that the formulations according to the invention have:
      • a pH-independent dissolution profile,
      • an in vivo release which prevents any peak in the plasma,
      • a bioavailability which is not decreased relative to an immediate-release formulation,
      • lower variability of the plasma kinetics results.

Claims (24)

1-7. (canceled)
8. A coated sustained release tablet, consisting essentially of from 0.5% to 12% by weight of mizolastine, a fatty matrix, an organic acid and a coating.
9. A coated sustained release tablet according to claim 8, which has a dissolution profile which is pH independent.
10. A coated sustained release tablet, consisting essentially of mizolastine, a fatty matrix, an organic acid, and a coating, the coated tablet having a dissolution profile which is pH independent, the organic acid being a member selected from the group consisting of maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid in the form of a racemate or an isomer.
11. A pharmaceutical dosage form which comprises a coated tablet having a sustained-release core, said core comprising a combination of:
a) mizolastine as active principle;
b) a fatty matrix; and
c) an organic acid;
wherein the coated tablet has a dissolution profile wherein about 50% of the mizolastine is dissolved in 1 hour, and 100% of the mizolastine is dissolved in 3 to 5 hours.
12. A sustained-release pharmaceutical dosage form according to claim 11 wherein the weight ratio of the mizolastine to the organic acid is between 0.3 and 1.
13. A sustained-release pharmaceutical dosage form according to claim 11 wherein the fatty matrix is a member selected from the group consisting of hydrogenated castor oil, a hydrogenated lecithin, a long-chain fatty acid and a triglyceride esterified with one, two or three medium-chain fatty acids.
14. A sustained-release pharmaceutical dosage form according to claim 11 wherein the organic acid is a member selected from the group consisting of maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid in the form of a racemate or an isomer.
15. A sustained-release pharmaceutical dosage form according to claim 11 wherein the organic acid is L-tartaric acid.
16. A sustained-release pharmaceutical dosage form according to claim 15 wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.
17. A sustained-release pharmaceutical dosage form according to claim 9 which contains from 1 to 25 mg of mizolastine.
18. A coated sustained-release tablet having:
a) a core comprising mizolastine, a fatty matrix and an organic acid;
b) a dissolution profile which is pH independent;
c) an in vivo mizolastine release which prevents any plasma peak; and
d) a mizolastine bioavailability which is not decreased relative to that of an immediate release formulation;
wherein the mizolastine comprises from 0.5% to 12% by weight of the tablet.
19. A sustained-release tablet of claim 18 wherein the dissolution profile is one in which about 30 to 70% of the mizolastine is dissolved in 1 hour and 100% of the mizolastine is dissolved in 3 to 5 hours.
20. A sustained-release tablet of claim 18 wherein the weight ratio between the mizolastine and the organic acid is between 0.3 and 1.
21. A sustained-release tablet of claim 18 wherein the fatty matrix is a member selected from the group consisting of hydrogenated castor oil, a hydrogenated lecithin, a long-chain fatty acid and a triglyceride esterified with one, two or three medium-chain fatty acids.
22. A sustained-release tablet of claim 18 wherein the organic acid is a member selected from the group consisting of maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid in the form of a racemate or an isomer.
23. A sustained-release tablet of claim 18 wherein the organic acid is L-tartaric acid.
24. A sustained-release tablet of claim 23 wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.
25. A sustained-release tablet of claim 18 wherein the core contains from 1 to 25 mg of mizolastine.
26. A sustained-release tablet of claim 18 wherein the organic acid has a pK of 2 or more.
27. A coated sustained-release tablet comprising from 1 to 25 mg of mizolastine, a fatty matrix and L-tartaric acid, and the weight ratio of the mizolastine and the L-tartaric acid is between 0.3 and 1.
28. A coated sustained-release tablet of claim 27, wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.
29. A coated sustained-release tablet of claim 28, wherein the fatty matrix is hydrogenated castor oil.
30. A coated sustained-release tablet of claim 29, wherein the tablet has a dissolution profile which is independent of pH and is one in which about 50% of the mizolastine is dissolved in 1 hour and 100% of the mizolastine is dissolved in 3 to 5 hours.
US11/027,680 1996-03-04 2005-01-03 Sustained-release pharmaceutical formulations containing mizolastine Abandoned US20050202089A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/027,680 US20050202089A1 (en) 1996-03-04 2005-01-03 Sustained-release pharmaceutical formulations containing mizolastine

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9602662 1996-03-04
FR9602662A FR2745500B1 (en) 1996-03-04 1996-03-04 SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTINE
PCT/FR1997/000355 WO1997032584A1 (en) 1996-03-04 1997-02-28 Slow-release pharmaceutical formulations containing mizolastin
US09/125,810 US6165507A (en) 1996-03-04 1997-02-28 Slow-release pharmaceutical formulations containing mizolastine
US60505400A 2000-06-28 2000-06-28
US11/027,680 US20050202089A1 (en) 1996-03-04 2005-01-03 Sustained-release pharmaceutical formulations containing mizolastine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US60505400A Continuation 1996-03-04 2000-06-28

Publications (1)

Publication Number Publication Date
US20050202089A1 true US20050202089A1 (en) 2005-09-15

Family

ID=9489799

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/125,810 Expired - Lifetime US6165507A (en) 1996-03-04 1997-02-28 Slow-release pharmaceutical formulations containing mizolastine
US11/027,680 Abandoned US20050202089A1 (en) 1996-03-04 2005-01-03 Sustained-release pharmaceutical formulations containing mizolastine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/125,810 Expired - Lifetime US6165507A (en) 1996-03-04 1997-02-28 Slow-release pharmaceutical formulations containing mizolastine

Country Status (35)

Country Link
US (2) US6165507A (en)
EP (1) EP0906101B1 (en)
JP (2) JP2000512617A (en)
KR (1) KR100369888B1 (en)
CN (1) CN1112929C (en)
AR (1) AR006082A1 (en)
AT (1) ATE219365T1 (en)
AU (1) AU725494B2 (en)
BG (1) BG63451B1 (en)
BR (1) BR9707827A (en)
CA (1) CA2247405C (en)
CO (1) CO4780020A1 (en)
CY (1) CY2293B1 (en)
CZ (1) CZ291418B6 (en)
DE (1) DE69713505T2 (en)
DK (1) DK0906101T3 (en)
EE (1) EE03511B1 (en)
ES (1) ES2177942T3 (en)
FR (1) FR2745500B1 (en)
HK (1) HK1017999A1 (en)
HU (1) HU227472B1 (en)
IL (1) IL126050A (en)
IN (1) IN187739B (en)
NO (1) NO315841B1 (en)
NZ (1) NZ331947A (en)
OA (1) OA10854A (en)
PL (1) PL189813B1 (en)
PT (1) PT906101E (en)
RU (1) RU2173997C2 (en)
SK (1) SK282112B6 (en)
TR (1) TR199801574T2 (en)
TW (1) TW491711B (en)
UA (1) UA49004C2 (en)
WO (1) WO1997032584A1 (en)
ZA (1) ZA971830B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (en) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd Sustained release tablet
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CA2518442A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (en) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
JP5744412B2 (en) * 2010-03-26 2015-07-08 テバ製薬株式会社 Furosemide formulation
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (en) * 1985-09-11 1987-10-30 Synthelabo BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JPH0776172B2 (en) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 Matrice locks
JPS62283926A (en) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd Long-acting composition of nicardipine hydrochloride
DE3812799A1 (en) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh ORGANIC PREPARATION FOR THE PURPOSES OF AN ACTUATED ACTIVE INGREDIENTS AND METHOD OF PREPARING THEM
JP3195391B2 (en) * 1991-11-14 2001-08-06 エスエス製薬株式会社 Sustained-release trapidil tablets
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
JPH07112932A (en) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc Sustained release medicine preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition

Also Published As

Publication number Publication date
TW491711B (en) 2002-06-21
FR2745500A1 (en) 1997-09-05
UA49004C2 (en) 2002-09-16
FR2745500B1 (en) 1998-04-03
RU2173997C2 (en) 2001-09-27
CZ279198A3 (en) 1999-01-13
ATE219365T1 (en) 2002-07-15
PL328763A1 (en) 1999-02-15
DE69713505D1 (en) 2002-07-25
SK121098A3 (en) 1999-01-11
EE9800275A (en) 1999-02-15
IN187739B (en) 2002-06-15
CZ291418B6 (en) 2003-03-12
HUP9902458A2 (en) 2000-05-28
WO1997032584A1 (en) 1997-09-12
US6165507A (en) 2000-12-26
CA2247405C (en) 2004-04-20
CN1112929C (en) 2003-07-02
BR9707827A (en) 1999-07-27
KR100369888B1 (en) 2003-05-17
EP0906101B1 (en) 2002-06-19
HUP9902458A3 (en) 2002-11-28
IL126050A0 (en) 1999-05-09
HK1017999A1 (en) 1999-12-10
SK282112B6 (en) 2001-11-06
CY2293B1 (en) 2003-07-04
IL126050A (en) 2004-05-12
AR006082A1 (en) 1999-08-11
DE69713505T2 (en) 2003-02-13
NZ331947A (en) 2000-03-27
AU1930097A (en) 1997-09-22
EE03511B1 (en) 2001-10-15
KR19990087387A (en) 1999-12-27
CA2247405A1 (en) 1997-09-12
JP2007182451A (en) 2007-07-19
PL189813B1 (en) 2005-09-30
OA10854A (en) 2003-02-05
PT906101E (en) 2002-09-30
HU227472B1 (en) 2011-07-28
EP0906101A1 (en) 1999-04-07
JP2000512617A (en) 2000-09-26
NO984035L (en) 1998-10-22
CO4780020A1 (en) 1999-05-26
BG102692A (en) 1999-04-30
NO984035D0 (en) 1998-09-02
ZA971830B (en) 1997-09-04
AU725494B2 (en) 2000-10-12
DK0906101T3 (en) 2002-10-14
TR199801574T2 (en) 1998-11-23
BG63451B1 (en) 2002-02-28
CN1212624A (en) 1999-03-31
ES2177942T3 (en) 2002-12-16
NO315841B1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
EP1096937B1 (en) Sustained release ranolazine formulations
JP2007182451A (en) Sustained-release pharmaceutical formulation containing mizolastine
BG64168B1 (en) Fast dissoluble tablet based on galantamine hydrobromine
US20100291204A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use thereof
US20060034928A1 (en) Tablet comprising cetirizine and pseudoephedrine
US20230381191A1 (en) Formulations of viloxazine
KR100926410B1 (en) Tablet comprising cetirizine and pseudoephedrine
AU2002345024A1 (en) Tablet comprising cetirizine and pseudoephedrine
WO2007049868A1 (en) Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
US20050171119A1 (en) Pharmaceutical formulations with modified release
US20070231390A1 (en) Formulations including hygroscopic compounds

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION